{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:06:19Z","timestamp":1779116779645,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100016318","name":"Cerus Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood donor eligibility policies may exclude individuals based on medication use, but the donor health questionnaire may not reliably capture all prescriptions. This study evaluates the capacity of the compound adsorption device (CAD) within the INTERCEPT Blood System Pathogen Reduction Technology (PRT) for plasma to remove exogenous testosterone and high doses of two drugs on the FDA donor deferral list.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design and Methods<\/jats:title>\n                    <jats:p>Plasma was manufactured from male whole blood donors undergoing testosterone replacement therapy (TRT) or whole blood donors with no medication history to be supplemented with supratherapeutic concentrations of apixaban, a common anticoagulant, and escalating doses of emtricitabine and tenofovir (FTC&amp;TFV) to note any saturating effects of removal. Plasma units were treated with INTERCEPT PRT only using the amotosalen and CAD steps without photochemical activation. Quantitative assays analyzed pre\u2010 and post\u2010CAD samples. Statistical analysis was performed using a Wilcoxon signed\u2010rank test and one\u2010way ANOVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CAD reduced the mean free and total testosterone by 75% (pre\u2010CAD 107.4, post\u2010CAD 26.8\u2009pg\/mL) and 74% (pre\u2010CAD 352.2, post\u2010CAD 85.7\u2009ng\/mL), respectively. Apixaban was removed below the limit of detection (pre\u2010CAD mean 420, post\u2010CAD mean &lt;23\u2009ng\/mL). Regardless of the initial dose, FTC&amp;TFV concentrations decreased by 100% and 98%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The INTERCEPT PRT plasma kit CAD effectively removed multiple drug classes, suggesting a potential role in mitigating drug contamination in transfusable plasma products. These findings may support the reconsideration of some medication\u2010based donor deferrals where the risk\u2013benefit of donor safety and product efficacy favors collection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.18485","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:25:24Z","timestamp":1764159924000},"page":"18-23","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components"],"prefix":"10.1111","volume":"66","author":[{"given":"Briana","family":"Greenwall","sequence":"first","affiliation":[{"name":"ARUP Laboratories  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Reeder","sequence":"additional","affiliation":[{"name":"ARUP Laboratories  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem Qais","family":"Anani","sequence":"additional","affiliation":[{"name":"ARUP Laboratories  Salt Lake City Utah USA"},{"name":"University of Utah  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Prescription drug use in the United States, 2015\u20132016. NCHS data brief, no 334","author":"Martin CB","year":"2019"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13391"},{"key":"e_1_2_10_4_1","unstructured":"Regulation (EU) 2024\/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing (Directives 2002\/98\/EC and 2004\/23\/EC) Document 32024R1938.https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=OJ:L_202401938"},{"key":"e_1_2_10_5_1","volume-title":"Memorandum: deferral of blood and plasma donors\u2013medications: CBER Office of Communications, Outreach, and Development","author":"Food and Drug Administration","year":"1993"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100328"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000203355"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2005.04316.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18149"},{"key":"e_1_2_10_10_1","unstructured":"HeiD.Method and devices for the removal of psoralens from blood products.2002."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(80)90473-X"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2158"},{"key":"e_1_2_10_13_1","volume-title":"ELIQUIS (apixaban) tablets for oral use [package insert]","year":"2012"},{"key":"e_1_2_10_14_1","volume-title":"TRUVADA (emtricitabine\/tenofovir disoproxil fumarate) tablets, for oral use [package insert]","year":"2004"},{"issue":"4","key":"e_1_2_10_15_1","first-page":"S19","article-title":"Supplemental findings of the 2021 National Blood Collection and Utilization Survey","volume":"63","author":"Kracalik I","year":"2023","journal-title":"Transfusion"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00909.x"},{"key":"e_1_2_10_17_1","volume-title":"INTERCEPT blood system for platelets\u2014large volume (LV) processing set [package insert]","year":"2016"},{"key":"e_1_2_10_18_1","volume-title":"INTERCEPT blood system for plasma [package insert]","year":"2014"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026863"},{"key":"e_1_2_10_20_1","first-page":"93A","article-title":"Are donors on anticoagulants or platelet antagonists at higher risk of hematoma?","volume":"55","author":"Townsend M","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006890"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.06.019"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1403-25"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.5958\/0974-4150.2020.00039.5"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.18485","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:09:45Z","timestamp":1779113385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.18485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/trf.18485"],"URL":"https:\/\/doi.org\/10.1111\/trf.18485","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2025-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}